EBITDA Margin: 42.64%
Is the EBITDA margin high or low?
The EBITDA margin of 42.64% is 75% above its 5-year average of 24.30%, near the high end of its 5-year range (-14.37%–42.64%).
As of Friday, June 26, 2026. 47.31% above its 12-month average of 28.95%.
STE EBITDA Margin
Reported quarterly EBITDA margin; no daily interpolation.
STE Average EBITDA Margin Chart
STE Current vs Average EBITDA Margin Chart
STE EBITDA Margin Metrics
EBITDA MARGIN
42.64%
EBITDA MARGIN AVG TTM
28.95%
EBITDA MARGIN AVG 3Y
26.58%
EBITDA MARGIN AVG 5Y
25.76%
EBITDA MARGIN AVG 10Y
24.08%
EBITDA MARGIN AVG 15Y
21.70%
EBITDA MARGIN AVG 20Y
20.67%
CURRENT VS TTM AVG
+47.31%
CURRENT VS 3Y AVG
+60.43%
CURRENT VS 5Y AVG
+65.55%
CURRENT VS 10Y AVG
+77.09%
CURRENT VS 15Y AVG
+96.52%
CURRENT VS 20Y AVG
+106.30%
STE Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| STERIS plc (STE) | $21.00B | 42.64% | 28.95% | 26.58% | 25.76% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 15.75% | 14.53% | 14.10% | 17.90% |
| Incyte Corporation (INCY)vs › | $22.73B | 27.93% | 16.21% | 17.95% | 14.24% |
| Viatris Inc. (VTRS)vs › | $19.02B | 0.95% | 10.32% | 17.98% | 18.96% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 50.36% | 50.37% | 51.80% | 47.75% |
| BioNTech SE (BNTX)vs › | $23.07B | -9.29% | -23.11% | 12.60% | 20.38% |
| Quest Diagnostics Incorporated (DGX)vs › | $23.08B | 19.69% | 19.16% | 18.89% | 21.02% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.01B | 29.84% | 29.78% | 28.27% | 25.91% |
| Waters Corporation (WAT)vs › | $24.41B | 34.73% | 34.58% | 34.05% | 33.84% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.79B | 24.13% | 25.03% | 27.36% | 27.53% |
Margin Comparison
Gross Margin
44.3%
EBITDA Margin
42.6%
Operating Margin
18.6%
Net Margin
13.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EBITDA Margin FAQ
- What is the EBITDA margin for STERIS plc (STE)?
- The EBITDA margin for STE stock is 42.64%.
- Is STERIS plc's EBITDA margin high or low?
- The EBITDA margin of 42.64% is 75% above its 5-year average of 24.30%, near the high end of its 5-year range (-14.37%–42.64%).
- What is the TTM average EBITDA margin for STERIS plc (STE)?
- The TTM average EBITDA margin for STE stock is 28.95%.
- What is the 3Y average EBITDA margin for STERIS plc (STE)?
- The 3Y average EBITDA margin for STE stock is 26.58%.
- What is the 5Y average EBITDA margin for STERIS plc (STE)?
- The 5Y average EBITDA margin for STE stock is 25.76%.
- What is the 10Y average EBITDA margin for STERIS plc (STE)?
- The 10Y average EBITDA margin for STE stock is 24.08%.
- What is the 15Y average EBITDA margin for STERIS plc (STE)?
- The 15Y average EBITDA margin for STE stock is 21.70%.
- What is the 20Y average EBITDA margin for STERIS plc (STE)?
- The 20Y average EBITDA margin for STE stock is 20.67%.
STE EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 42.64% |
| 2025-12-31 | 26.27% |
| 2025-09-30 | 26.69% |
| 2025-06-30 | 26.27% |
| 2025-03-31 | 22.86% |
| 2024-12-31 | 27.08% |
| 2024-09-30 | 25.20% |
| 2024-06-30 | 23.31% |
| 2024-03-31 | 34.02% |
| 2023-12-31 | 28.29% |
| 2023-09-30 | 27.77% |
| 2023-06-30 | 28.37% |
| 2023-03-31 | 26.55% |
| 2022-12-31 | 27.04% |
| 2022-09-30 | -14.37% |
| 2022-06-30 | 25.70% |
| 2022-03-31 | 26.90% |
| 2021-12-31 | 26.51% |
| 2021-09-30 | 19.59% |
| 2021-06-30 | 10.11% |
| 2021-03-31 | 23.48% |
| 2020-12-31 | 25.20% |
| 2020-09-30 | 25.88% |
| 2020-06-30 | 24.63% |
| 2020-03-31 | 25.36% |
| 2019-12-31 | 24.79% |
| 2019-09-30 | 23.94% |
| 2019-06-30 | 22.56% |
| 2019-03-31 | 24.88% |
| 2018-12-31 | 21.87% |
| 2018-09-30 | 22.49% |
| 2018-06-30 | 22.12% |
| 2018-03-31 | 22.08% |
| 2017-12-31 | 22.35% |
| 2017-09-30 | 22.72% |
| 2017-06-30 | 21.22% |
| 2017-03-31 | 16.37% |
| 2016-12-31 | 8.85% |
| 2016-09-30 | 18.51% |
| 2016-06-30 | 19.94% |
| 2016-03-31 | 22.04% |
| 2015-12-31 | 14.80% |
| 2015-09-30 | 9.47% |
| 2015-06-30 | 15.13% |
| 2015-03-31 | 18.02% |
| 2014-12-31 | 17.53% |
| 2014-09-30 | 17.47% |
| 2014-06-30 | 15.65% |
| 2014-03-31 | 17.10% |
| 2013-12-31 | 18.61% |
| 2013-09-30 | 17.74% |
| 2013-06-30 | 16.14% |
| 2013-03-31 | 20.00% |
| 2012-12-31 | 22.47% |
| 2012-09-30 | 21.93% |
| 2012-06-30 | 18.59% |
| 2012-03-31 | 23.23% |
| 2011-12-31 | 19.66% |
| 2011-09-30 | 18.50% |
| 2011-06-30 | 19.25% |
| 2011-03-31 | 19.09% |
| 2010-12-31 | 15.01% |
| 2010-09-30 | 21.82% |
| 2010-06-30 | -26.44% |
| 2010-03-31 | 19.74% |
| 2009-12-31 | 22.46% |
| 2009-09-30 | 20.37% |
| 2009-06-30 | 20.01% |
| 2009-03-31 | 18.15% |
| 2008-12-31 | 18.82% |
| 2008-09-30 | 18.98% |
| 2008-06-30 | 16.13% |
| 2008-03-31 | 15.29% |
| 2007-12-31 | 15.76% |
| 2007-09-30 | 14.36% |
| 2007-06-30 | 13.22% |
| 2007-03-31 | 19.39% |
| 2006-12-31 | 16.20% |
| 2006-09-30 | 37.74% |
| 2006-06-30 | 15.22% |
| 2006-03-31 | 10.39% |
| 2005-12-31 | 18.34% |
| 2005-09-30 | 37.41% |
| 2005-06-30 | 15.11% |
| 2005-03-31 | 18.97% |
| 2004-12-31 | 18.91% |
| 2004-09-30 | 16.42% |
| 2004-06-30 | 15.59% |
| 2004-03-31 | 18.98% |
| 2003-12-31 | 18.38% |
| 2003-09-30 | 17.31% |
| 2003-06-30 | 14.62% |
| 2003-03-31 | 19.70% |
| 2002-12-31 | 18.43% |
| 2002-09-30 | 17.83% |
| 2002-06-30 | 14.39% |
Related Metrics
About STERIS plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Daniel A. Carestio